Topical<scp>beta‐blockers</scp>in dermatologic therapy

Filoni, Angela; Ambrogio, Francesca; Marco, Aurora De; Pacifico, Alessia; Bonamonte, Domenico

doi:10.1111/dth.15016

Cited by 25 publications

(16 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They can postpone or obviate surgical treatment, especially in children, for whom they are the first-line treatment, also, in large lesions by reducing its size. The only limitation of beta-blockers here is their inability to perform histological examinations [ 48 ]. Although the adverse effects and systemic absorption appeared to be negligible in all included studies, further research is needed to identify the maximal dosage and duration.…”

Section: Discussionmentioning

confidence: 99%

The Role of Systemic and Topical Beta-Blockers in Dermatology: A Systematic Review

Alhazmi

Basendwh

Aman

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction: Beta-blockers are proven to be safe and cost-effective agents in treating multiple dermatological conditions, which is why they are considered as an interesting and good alternative therapeutic agent by dermatologists. To our knowledge, there has been no comprehensive systematic review to date summarizing the role of both systemic and topical betablockers in dermatology. Methods: In this systematic review, we aim to review recent and relevant published literature in order to provide a comprehensive evidencebased summary to inform dermatologists. Results: An electronic-based literature search was carried out during October-December 2021 in the databases PubMed (MEDLINE), SCOPUS (EMBASE), and Cochrane Library. Furthermore, bibliographic sources were also reviewed for the selected articles. We followed The Preferred Reporting Items for Systematic Reviews and Meta-analyses 2020 (PRISMA) guidelines. We reviewed published literature about the role of beta-blockers in dermatology for the time period (January 2016 to December 2021). Conclusions: A total of 126 publications were retrieved from different databases, of which 59 studies were finally included in our review after excluding non-eligible literature in accordance with our inclusion and exclusion criteria. The included articles consisted of meta-analyses, systematic reviews, clinical trials, retrospective and prospective cohort studies, case-control studies, case series, and case reports. In general, data in reviewed literature showed that both systemic and topical beta-blockers were reliable and safe therapeutic options in treating different dermatoses. Their effect has been studied as a mono-therapy, also as an adjuvant therapy combined with other current disease-specific therapeutic modalities such as lasers, radiation, chemotherapy, corticosteroids, or other betablockers options. Local and systemic adverse effects were mainly minor and non-significant.

show abstract

Section: Discussionmentioning

confidence: 99%

The Role of Systemic and Topical Beta-Blockers in Dermatology: A Systematic Review

Alhazmi

Basendwh

Aman

et al. 2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…22 Owning to growing evidences and clinical experiences, increasing topical beta-blocker use in dermatologic disease is described in recent decade including hemangioma, Kaposi sarcoma, wound healing, paronychia and pseudopyogenic granuloma. 23 Olamiju et al demonstrated a case series with 10 EGFR-TKI-related paronychia patients who were treated with topical timolol 0.5% twice daily under occlusion. Nine patients needed adjunct dermatologic therapy including topical antibiotic, steroid or even silver nitrate cauterization.…”

Section: Discussionmentioning

confidence: 99%

Combination of available topical beta-blockers and antibiotic ointment for epidermal growth factor receptor tyrosine kinase inhibitor-induced paronychia and pseudopyogenic granulomas in Taiwan

Liu

Chuang

et al. 2022

J Oncol Pharm Pract

View full text Add to dashboard Cite

Background Painful paronychia and pseudopyogenic granuloma (PG) are common adverse drug reactions (ADRs) associated with the use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) to treat non-small cell lung cancer (NSCLC). Multiple local management approaches have been tested with unsatisfactory results. We have introduced an occlusion therapy technique through which available topical drugs for longer than 2 years. Methods Based on the cancer registry and case management system of our hospital, from July 2019 to July 2020, we retrospectively enrolled patients with NSCLC who were treated with EGFR-TKIs and received applications of 0.5% timolol ophthalmic solution (TIMOPTOL XE 0.5%®) combined with a neomycin/tyrothricin ointment ( Biomycin®) using the occlusion method to treat paronychia or PG. Results A total of 22 patients were enrolled, with a mean age of 66.5 years, most of whom were women (72.7%). Periungual lesion-related pain was reported by all patients, and periungual bleeding and PG were reported in 14% (3/22) and 64% (14/22) of patients, respectively. After the occlusion therapy application of timolol ophthalmic solution combined with neomycin/tyrothricin ointment twice daily, the overall response rate was 83.3%, including complete response in 18% (4/22) of cases and partial response in 68% (15/22) of cases. Conclusion We presented an occlusion method using available topical beta-blockers and antibiotic ointment for EGFR-TKI-induced paronychia and PG in Taiwan. The result is favorable. Further randomized control trial is urgent to validate our findings

show abstract

“…Eczema, ulcers, skin rashes, desquamation, and erythema are frequent adverse effects of topical timolol (Filoni et al, 2021). A large recent study in over 700 superficial IHs reported that 3.9% of patients treated with oral propranolol (2 mg/kg/day) presented systemic adverse events (AEs) while topical timolol treatment (0.5% hydrogel, three times daily) did not cause AEs (Wu et al, 2018).…”

Section: Adverse Eventsmentioning

confidence: 99%

Update on Treatment of Infantile Hemangiomas: What’s New in the Last Five Years?

et al. 2022

View full text Add to dashboard Cite

Among benign vascular tumors of infancy, hemangiomas are the commonest, affecting approximately 5–10% of one-year-old children. They are derived from a benign proliferation of vascular endothelial cells (VECs) in the mesoderm and may arise anywhere on the body around 1–2 weeks after birth. Infantile hemangiomas (IHs) are characterized by an early proliferative phase in the first year followed by a spontaneous progressive regression within the following 5 years or longer. IH prevalence is estimated to be 5%–10% in one-year-old children and commonly affects female, Caucasian and low-birth weight infants. Although most of them spontaneously regress, approximately 10% requires treatment to prevent complications due to the site of occurrence such as bleeding, ulceration, cosmetically disfigurement, functional impairment, or life-threatening complications. For over 30 years, steroids have represented the first-line treatment for IHs, but recently topical or systemic β-blockers are increasingly being used and recognized as effective and safe. A search for “Cutaneous infantile hemangioma” [All Fields] AND “Treatment” [All Fields] was performed by using PubMed and EMBASE databases. Treatment of IHs with labeled drugs, such as oral propranolol, but also with off-label drugs, such as topical β-blockers, including topical timolol and carteolol, steroids, itraconazole or sirolimus, with a focus on formulations types and adverse events were described in our review. We also discussed the benefits of pulsed dye laser and the treatment of IHs with involvement of central nervous system, namely the PHACE and LUMBAR syndrome.

show abstract

Topicalbeta‐blockersin dermatologic therapy

Cited by 25 publications

References 50 publications

The Role of Systemic and Topical Beta-Blockers in Dermatology: A Systematic Review

The Role of Systemic and Topical Beta-Blockers in Dermatology: A Systematic Review

Combination of available topical beta-blockers and antibiotic ointment for epidermal growth factor receptor tyrosine kinase inhibitor-induced paronychia and pseudopyogenic granulomas in Taiwan

Update on Treatment of Infantile Hemangiomas: What’s New in the Last Five Years?

Contact Info

Product

Resources

About